Deutsch English Français

Contact

EP2305282

European procedure

Quick help

Maintenance news

Misleading Register Alert event notification on 15.04.19

Following a clean-up exercise of event information regarding (previously) revoked patents, that were later reinstated, some existing revocation events ("Despatch of communication that patent is revoked") were duplicated on 15.04.2019.

2019.04.15

More...

News flashes

European Patent Register Assistant updated

In order to offer you the best possible learning experience we have launched an updated version of the European Patent Register Assistant online tutorial to include recent changes in the Register.

2019.08.29

More...

Extract from the Register of European Patents

About this file: EP2305282

EP2305282 - Prevention and treatment of amyloidogenic disease [Right-click to bookmark this link]
Status	Patent revoked Status updated on 18.11.2016 Database last updated on 21.09.2019
Most recent event Tooltip	13.01.2017	Lapse of the patent in a contracting state New state(s): CH, LI	published on 15.02.2017 [2017/07]
Applicant(s)	For all designated states Janssen Alzheimer Immunotherapy Airton Road Tallaght Dublin 24 / IE
	[2013/28]
Former [2011/14]	For all designated states Janssen Alzheimer Immunotherapy Little Island Industrial Estate Little Island, County Cork / IE
Inventor(s)	01 / Schenk, Dale B. 1542 Los Altos Drive Burlingame, CA 94010 / US
	[2013/28]
Former [2011/14]	01 / Schenk, Dale B. 1542 Los Altos Drive Burlingame, CA 94010 / US
Representative(s)	Bullett, Rachel Margaret , et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2011/14]	Bullett, Rachel Margaret , et al Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB
Application number, filing date	10182575.0	30.11.1998
	[2011/14]
Priority number, date	US19970067740P	02.12.1997 Original published format: US 67740 P
	US19980080970P	07.04.1998 Original published format: US 80970 P
	[2011/14]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2305282
	Date:	06.04.2011
	Language:	EN
	[2011/14]
	Type:	A3 Search report
	No.:	EP2305282
	Date:	18.05.2011
	[2011/20]
	Type:	B1 Patent specification
	No.:	EP2305282
	Date:	10.07.2013
	Language:	EN
	[2013/28]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	14.04.2011
Classification	International:	A61K38/00, A61K38/28, A61K9/26, A61K33/06	[2011/14]
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2011/14]
Extension states	AL	17.11.2011
	LT	17.11.2011
	LV	17.11.2011
	MK	01.12.2011
	RO	17.11.2011
	SI	17.11.2011
Title	German:	Vorbeugung und Behandlung von amyloidogener Krankheit	[2011/14]
	English:	Prevention and treatment of amyloidogenic disease	[2011/14]
	French:	Prévention et traitement de maladie amyloidogène	[2011/14]
Examination procedure	17.11.2011	Examination requested [2011/52]
	28.12.2011	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
	07.03.2012	Amendment by applicant (claims and/or description)
	21.05.2012	Despatch of a communication from the examining division (Time limit: M02)
	29.05.2012	Observations by third parties
	31.07.2012	Reply to a communication from the examining division
	17.01.2013	Communication of intention to grant the patent
	22.05.2013	Fee for grant paid
	22.05.2013	Fee for publishing/printing paid
Parent application(s) Tooltip	EP08011409.3 / EP1994937
	EP98961833.5 / EP1033996
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP19980961833) is 02.08.2005
Opposition(s)	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen Howard Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 28.09.2015 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 225 Binney Street Cambridge MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patent- und Rechtsanwälte PartmbB Postfach 860 820 81635 München / DE
		[N/P]
	Former [2016/24]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 28.09.2015 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 225 Binney Street Cambridge MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte PartmbB Postfach 860 820 81635 München / DE
	Former [2015/45]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 28.09.2015 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 250 Binney Street Cambridge, MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2015/43]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 14.05.2014 ADMISSIBLE Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 250 Binney Street Cambridge, MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2015/38]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 14.05.2014 ADMISSIBLE Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Idec Inc. 133 Boston Post Road Weston, MA 02493 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2015/35]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Woods, Geoffrey Corlett J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 14.05.2014 ADMISSIBLE Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Idec Inc. 133 Boston Post Road Weston, MA 02493 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2014/21]
	Opponent(s)	01 09.04.2014 Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Siebertstrasse 4 81675 München / DE
		03 10.04.2014 Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Woods, Geoffrey Corlett J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative HOFFMANN EITLE Patent- und Rechtsanwälte Arabellastrasse 4 81925 München / DE
		05 10.04.2014 Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 Biogen Idec MA Inc. 133 Boston Post Road Weston, MA 02493 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2014/20]
	Opponent(s)	01 09.04.2014 Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Siebertstrasse 4 81675 München / DE
		03 10.04.2014 Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Woods, Geoffrey Corlett J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	23.05.2014	Invitation to proprietor to file observations on the notice of opposition
	03.02.2015	Reply of patent proprietor to notice(s) of opposition
	01.10.2015	Cancellation of oral proceeding that was planned for 28.04.2016
	28.04.2016	Date of oral proceedings
	08.06.2016	Cancellation of oral proceeding that was planned for 22.06.2016
	22.06.2016	Date of oral proceedings
	04.07.2016	Despatch of communication that the patent will be revoked
	09.11.2016	Legal effect of revocation of patent [2016/51]
Appeal following opposition	14.09.2016	Appeal received No. T2144/16
	09.11.2016	Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	07.03.2012	Request for further processing filed
	07.03.2012	Full payment received (date of receipt of payment) Request granted
	22.03.2012	Decision despatched
Fees paid	Renewal fee
	27.01.2011	Renewal fee patent year 03
	27.01.2011	Renewal fee patent year 04
	27.01.2011	Renewal fee patent year 05
	27.01.2011	Renewal fee patent year 06
	27.01.2011	Renewal fee patent year 07
	27.01.2011	Renewal fee patent year 08
	27.01.2011	Renewal fee patent year 09
	27.01.2011	Renewal fee patent year 10
	27.01.2011	Renewal fee patent year 11
	27.01.2011	Renewal fee patent year 12
	27.01.2011	Renewal fee patent year 13
	14.11.2011	Renewal fee patent year 14
	13.11.2012	Renewal fee patent year 15
Lapses during opposition Tooltip	CH	10.07.2013
	CY	10.07.2013
	LI	10.07.2013
	MC	10.07.2013
	[2017/07]
Former [2014/33]	CY	10.07.2013
	MC	10.07.2013
Former [2014/10]	CY	10.07.2013
Documents cited:	Search	[XY]WO9116819 (MOLECULAR RX., INC) [X] 1-3,5,12,13 * the whole document * [Y] 6-10,14,15;
		[X]EP0683234 (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [X] 1-3,12,13 * the whole document *;
		[Y]WO9400153 (SMITHKLINE BEECHAM BIOLOGICALS) [Y] 1-15 * the whole document *;
		[Y] - SAITO Y ET AL, "Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (199510), vol. 92, no. 22, ISSN 0027-8424, pages 10227 - 10231, XP002090767 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.92.22.10227
		[Y] - WU ET AL, "Drug targeting of a peptide radiopharmaceutical through the primate blood - brain barrier in vivo with a monoclonal antibody to the human insulin receptor", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, (199710), vol. 100, no. 7, ISSN 0021-9738, pages 1804 - 1812, XP002090766 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1172/JCI119708
		[Y] - URMONEIT B ET AL, "CEREBROVASCULAR SMOOTH MUSCLE CELLS INTERNALIZE ALZHEIMER AMYLOID BETA PROTEIN VIA A LIPOPROTEIN PATHWAY: IMPLICATIONS FOR CEREBRAL AMYLOID ANGIOPATHY", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, (199708), vol. 77, no. 2, ISSN 0023-6837, pages 157 - 166, XP002940016 [Y] 1-15 * the whole document *
		[Y] - DU Y ET AL, "alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein.", JOURNAL OF NEUROCHEMISTRY. JUL 1997, (199707), vol. 69, no. 1, ISSN 0022-3042, pages 299 - 305, XP002381632 [Y] 1-15 * the whole document *
		[Y] - LADU M J ET AL, "Isoform-specific binding of apolipoprotein E to beta-amyloid.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 23 SEP 1994, (19940923), vol. 269, no. 38, ISSN 0021-9258, pages 23403 - 23406, XP002381631 [Y] 1-15 * the whole document *
		[Y] - JOHNSON-WOOD K ET AL, "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (19970218), vol. 94, no. 4, ISSN 0027-8424, pages 1550 - 1555, XP002275435 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.94.4.1550
		[Y] - SOLOMON B ET AL, "DISAGGREGATION OF ALZHEIMER BETA-AMYLOID BY SITE-DIRECTED MAB", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, (19970401), vol. 94, doi:DOI:10.1073/PNAS.94.8.4109, ISSN 0027-8424, pages 4109 - 4112, XP002911322 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.94.8.4109
		[Y] - YANG FUSHENG ET AL, "MONOCLONAL ANTIBODY TO THE C-TERMINUS OF BETA-AMYLOID", NEUROREPORT, LIPPINCOTT WILLIAMS & WILKINS, US, (19940101), vol. 5, no. 16, doi:DOI:10.1097/00001756-199410270-00032, ISSN 0959-4965, pages 2117 - 2120, XP009084989 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1097/00001756-199410270-00032
		[Y] - MANN D M A ET AL, "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (19960401), vol. 148, no. 4, ISSN 0002-9440, pages 1257 - 1266, XP002503136 [Y] 1-15 * the whole document *
		[Y] - SCHMIDT M L ET AL, "Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (19970701), vol. 151, no. 1, ISSN 0002-9440, pages 69 - 80, XP002503137 [Y] 1-15 * the whole document *
		[Y] - IWATSUBO ET AL, "Visualization of ABeta42(43) and ABeta40 in senile plaques with end-specific AB monoclonals: Evidence that an initially deposited species is ABeta42(43)", NEURON, CAMBRIDGE, MA, US, (19940701), vol. 13, doi:DOI:10.1016/0896-6273(94)90458-8, pages 45 - 53, XP002089557 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/0896-6273(94)90458-8
		[Y] - MANN D M A ET AL, "ATYPICAL AMYLOID (ABETA) DEPOSITION IN THE CEREBELLUM IN ALZHEIMER'S DISEASE: AN IMMUNOHISTOCHEMICAL STUDY USING END-SPECIFIC ABETA MONOCLONAL ANTIBODIES", ACTA NEUROPATHOLOGICA, SPRINGER VERLAG, BERLIN, DE, (19960101), vol. 91, doi:DOI:10.1007/S004010050479, ISSN 0001-6322, pages 647 - 653, XP002942205 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1007/s004010050479
		[Y] - MURPHY G M ET AL, "DEVELOPMENT OF A MONOCLONAL ANTIBODY SPECIFIC FOR THE COOH-TERMINAL OF BETA-AMYLOID 1-42 AND ITS IMMUNOHISTOCHEMICAL REACTIVITY IN ALZHEIMER'S DISEASE AND RELATED DISORDERS", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (19940501), vol. 144, no. 5, ISSN 0002-9440, pages 1082 - 1088, XP000573948 [Y] 1-15 * the whole document *
		[Y] - GRAVINA S ET AL, "Amyloid beta protein (Abeta) in Alzheimer's disease brain", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, (19950331), vol. 270, no. 13, doi:DOI:10.1074/JBC.270.13.7013, ISSN 0021-9258, pages 7013 - 7016, XP002094143 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1074/jbc.270.13.7013
		[Y] - FRIEDLAND R P ET AL, "Neuroimaging of vessel amyloid in Alzheimer's disease", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, (19970926), vol. 826, doi:DOI:10.1111/J.1749-6632.1997.TB48475.X, ISSN 0077-8923, pages 242 - 247, XP002503138 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1111/j.1749-6632.1997.tb48475.x
		[Y] - SOLOMON B ET AL, "MONOCLONAL ANTIBODIES INHIBIT IN VITRO FIBRILLAR AGGREGATION OF THEALZHEIMER BETA-AMZLOID PEPTIDE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, (19960101), vol. 93, doi:DOI:10.1073/PNAS.93.1.452, ISSN 0027-8424, pages 452 - 455, XP002911321 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.93.1.452
		[Y] - SHINKAI Y ET AL, "Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels.", ANNALS OF NEUROLOGY. SEP 1995, (199509), vol. 38, no. 3, ISSN 0364-5134, pages 421 - 428, XP002381836 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1002/ana.410380312
		[YP] - FRENKEL D ET AL, "N-TERMINAL EFRH SEQUENCE OF ALZHEIMER'S BETA-AMYLOID PEPTIDE REPRESENTS THE EPITOPE OF ITS ANTI-AGGREGATING ANTIBODIES", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, (19980101), vol. 88, doi:DOI:10.1016/S0165-5728(98)00098-8, ISSN 0165-5728, pages 85 - 90, XP001001343 [YP] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0165-5728(98)00098-8
		[YP] - YANAGISAWA K ET AL, "Amyloid BETA-protein (ALPHA-BETA) associated with lipid molecules: immunoreactivity distinct from that of soluble ALPHA-BETA", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (19971222), vol. 420, no. 1, doi:DOI:10.1016/S0014-5793(97)01484-1, ISSN 0014-5793, pages 43 - 46, XP004261667 [YP] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0014-5793(97)01484-1
	by applicant	WO9213069
		EP0526511
		US4666829
		WO9512608
		WO9306121
		WO9408051
		WO9535503
		WO9530642
		WO9118980
		US5612486
		WO9007861
		WO9117271
		WO9201047
		WO9312227
		WO9110741
		US5314813
		WO9717613
		WO9717614
		WO9412629
		US5208036
		US5264618
		US5279833
		US5283185
		US5399346
		WO9505853
		GB2220211
		US5057540
		WO9014837
		- SELKOE, TINS, (1993), vol. 16, pages 403 - 409
		- SELKOE, J. NEUROPATHOL. EXP. NEUROL., (1994), vol. 53, pages 438 - 447
		- DUFF ET AL., NATURE, (1995), vol. 373, pages 476 - 477
		- GAMES ET AL., NATURE, (1995), vol. 373, page 523
		- GOATE ET AL., NATURE, (1991), vol. 349, page 704
		- CHARTIER HARLAN ET AL., NATURE, (1991), vol. 353, page 844
		- MURRELL ET AL., SCIENCE, (1991), vol. 254, page 97
		- MULLAN ET AL., NATURE GENET., (1992), vol. 1, page 345
		- SEUBERT ET AL., NATURE, (1992), vol. 359, pages 325 - 327
		- GUPTA, VACCINE, (1997), vol. 15, pages 1341 - 3
		- SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
		- NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
		- PEARSON; LIPMAN, PROC. NAT'L. ACAD. SCI. USA, (1988), vol. 85, page 2444
		- ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
		- HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, (1989), vol. 89, page 10915
		- KANG ET AL., NATURE, (1987), vol. 325, page 773
		- PONTE ET AL., NATURE, (1988), vol. 331, page 525
		- KITAGUCHI ET AL., NATURE, (1988), vol. 331, page 530
		- GLENN E. MORRIS,, Epitope Mapping Protocols in Methods in Molecular Biology, (1996), vol. 66
		- BURKE ET AL., J. INF. DIS., (1994), vol. 170, pages 1110 - 19
		- TIGGES ET AL., J. IMMUNOL., vol. 156, pages 3901 - 3910
		- WEISSMANN ET AL., CURR. OPIN. NEUROBIOL., (1997), vol. 7, pages 695 - 700
		- SMITS ET AL., VETERINARY QUARTERLY, (1997), vol. 19, pages 101 - 105
		- NATHANSON ET AL., AM. J. EPIDEMIOL., (1997), vol. 145, pages 959 - 969
		- GLENNER; WONG, BIOCHEM. BIOPHYS. RES. COMMUN., (1984), vol. 120, page 1131
		- HARDY, TINS, (1997), vol. 20, page 154
		- HARDY ET AL., TINS, (1997), vol. 20, pages 155 - 158
		- Essential Immunology, 6th ed., BLACKWELL SCIENTIFIC PUBLICATIONS, page 181
		- HSIAO ET AL., SCIENCE, (1996), vol. 274, page 99
		- STAUFENBIEL ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 13287 - 13292
		- STURCHLER-PIERRAT ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 13287 - 13292
		- BORCHELT ET AL., NEURON, (1997), vol. 19, pages 939 - 945
		- QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 10033
		- IMMUN. REV., (1982), vol. 62, page 185
		- LAWRIE; TUMIN, CUR. OPIN. GENET. DEVELOP., (1993), vol. 3, pages 102 - 109
		- BETT ET AL., J. VIROL., (1993), vol. 67, page 5911
	- ZHOU ET AL., J. EXP. MED., (1994), vol. 179, page 1867
	- DUBENSKY ET AL., J. VIROL., (1996), vol. 70, pages 508 - 519
	- OHE ET AL., HUMAN GENE THERAPY, (1995), vol. 6, pages 325 - 333
	- XIAO; BRANDSMA, NUCLEIC ACIDS. RES., (1996), vol. 24, pages 2630 - 2622
	- STOUTE ET AL., N. ENGL. J. MED., (1997), vol. 336, pages 86 - 91
	- LIVINGSTON, J. IMMUNOL., (1997), vol. 159, pages 1383 - 1392
	- CHANG ET AL., ADVANCED DRUG DELIVERY REVIEWS, (1998), vol. 32, pages 173 - 186
	- LANGER, SCIENCE, (1990), vol. 249, page 1527
	- HANES, ADVANCED DRUG DELIVERY REVIEWS, (1997), vol. 28, pages 97 - 119
	- GLENN ET AL., NATURE, (1998), vol. 391, page 851
	- PAUL ET AL., BUR. J. IMMUNOL., (1995), vol. 25, pages 3521 - 24
	- CEVC ET AL., BIOCHEM. BIOPHYS. ACTA, (1998), vol. 1368, pages 201 - 15
	- GAMES ET AL., NATURE
	- JOHNSON-WOOD ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 1550 - 1555
	- OLTERSDORF ET AL., J. BIOL. CHEM., (1990), vol. 265, pages 4492 - 4497
	- ESCH ET AL., SCIENCE, (1990), vol. 248, pages 1122 - 1124
	other	EP1690547
		EP1033996

Legal notice
Terms of use
18.2.18; 93p